VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study ; volume:14 ; number:1 ; day:9 ; month:4 ; year:2024 ; pages:1-4 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (9.4.2024), 1-4, 12.2024
- Creator
-
Nørgaard, Jakob Nordberg
Moore, Kari Lenita Falck
Slørdahl, Tobias S.
Vik, Anders
Tvedt, Tor Henrik Anderson
Schjesvold, Fredrik
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01047-1
- URN
-
urn:nbn:de:101:1-2406241147031.741285930965
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nørgaard, Jakob Nordberg
- Moore, Kari Lenita Falck
- Slørdahl, Tobias S.
- Vik, Anders
- Tvedt, Tor Henrik Anderson
- Schjesvold, Fredrik
- SpringerLink (Online service)
Other Objects (12)
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD
Gesundheitsunterlagen eines Unteroffiziers der VRD
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD
Gesundheitsunterlagen eines Unteroffiziers der VRD
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD